Bayesian secondary analysis of the GALFLU trial in adults aged 65–79: high-dose vs standard-dose inactivated influenza vaccine had >80% estimated probability of benefit (relative vaccine effectiveness >10%) against influenza- or pneumonia-related hospitalisation.
Secondary analysis
Pardo-Seco et al. A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes